AI Article Synopsis
- Plerixafor is a medication used with G-CSF to help collect stem cells from the blood for transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
- Research indicates that combining plerixafor with chemotherapy and G-CSF is generally safe and effective for most patients who struggle with low CD34(+) cell counts after mobilization or have had poor collection yields.
- The paper aims to explore ongoing debates regarding plerixafor and suggest future research opportunities for its use and development.
Article Abstract
Plerixafor, a hematopoietic stem cell mobilizer, is indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Current evidence suggests that the addition of plerixafor with chemotherapy plus G-CSF is safe and effective in the large majority of the patients with low blood CD34(+) cell count after mobilization and/or poor yield after the first collection. Nevertheless, there are several questions strongly debated, and in this paper, we would like to identify areas of possible future use and development of the drug.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14712598.2015.971750 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Protocol for differentiating hematopoietic progenitor cells from human pluripotent stem cells in chemically defined monolayer culture.
STAR Protoc
January 2025
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic address:
Human pluripotent stem cells (hPSCs) provide a powerful platform for generating hematopoietic progenitor cells (HPCs) and investigating hematopoietic development. Here, we present a protocol for maintaining hPSCs and inducing their differentiation into HPCs through the endothelial-to-hematopoietic transition (EHT) on vitronectin-coated plates. We outline steps for evaluating the efficiency of HPC generation and assessing their potential to differentiate into various hematopoietic lineages.
View Article and Find Full Text PDFThe role of fat-soluble vitamins for graft-versus host disease after myeloablative conditioning in allogeneic stem cell transplanted patients.
Sci Rep
January 2025
Department of Haematology, Oslo University Hospital, P.O. Box 4950, Oslo, 0424, Norway.
Whether the fat-soluble vitamins A, D, E, and K are associated with development of graft-versus-host disease (GvHD) after allogeneic stem cell transplantation, is unclear. We assessed if the levels of these vitamins were associated with development of GvHD during the first year after transplantation using data from a two-armed randomized nutritional intervention trial. Changes in plasma levels during 1-year follow-up were analyzed using a linear mixed model for repeated measurements.
View Article and Find Full Text PDFShould patients undergoing hematopoietic stem cell transplantation undergo screening and monitoring for skin cancer?
An Bras Dermatol
January 2025
Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Instituto de Investigación Sanitaria (IIS) La Fe, Valencia, Spain; Universitat de València, Valencia, Spain, Dermatology, Valencia, Spain. Electronic address:
Refining risk stratification for B-cell precursor Adult Acute Lymphoblastic Leukemia treated with a Pediatric-inspired Regimen by Combining IKZF1 deletion and Minimal Residual Disease.
Transplant Cell Ther
January 2025
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Electronic address:
Unlabelled: Minimal residual disease (MRD) is the most important prognostic factor for B-cell acute lymphoblastic leukemia (B-ALL) however nearly 20-30% of patients relapsed even when they achieved negative MRD, how to identify these patients is less addressed. In this study, we aimed to reassess the prognostic significance of MRD and IKZF1 in adult B-ALL patients receiving pediatric chemotherapy regimens. In the PDT-ALL-2016 cohort (NCT03564470), adult B-ALL patients were treated with a pediatric-inspired regimen; patients were redefined as standard (MRD-negative and IKZF1wild-type), intermediate (MRD-positive or IKZF1 deletion), and high-risk (MRD-positive and IKZF1 deletion) groups by combining IKZF1 deletion status and MRD.
View Article and Find Full Text PDFAllogeneic Hematopoietic Stem-Cell Transplant Recipients and Skin Cancer Risk: A Commercial Claims Cohort Study.
J Invest Dermatol
January 2025
Department of Health Services Research, University of Texas MD Anderson Cancer Center, TX; Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!